GLP-1 Analogues Market – Global Forecast to 2032
GLP-1 類似体市場 – 製品 (オゼンピック、リベルサス、サクセンダ、 ウゴービ、マンジャロ、ゼプバウンド、ビクトーザ、トルリシティ)、形式 (単回投与、複数回投与、錠剤)、ROA (皮下、経口)、適応症 (糖尿病、肥満) – 2032年までの世界予測
GLP-1 Analogues Market by Product (Ozempic, Rybelsus, Saxenda, Wegovy, Mounjaro, Zepbound, Victoza, Trulicity), Format (Single dose, Multi-dose, Tablets), ROA (Subcutaneous, Oral), Indication (Diabetes, Obesity) – Global Forecast to 2032
The GLP-1 Analogues market is expected to reach USD 471.1 billion by 2032 from USD 47.4 billion in 2024, at a CAGR of 33.2% during the forecast period.
GLP-1 類似体市場は、予測期間中に 33.2% の CAGR で、2024 年の 474 億米ドルから 2032 年までに 4,711 億米ドルに達すると予想されます。
The report provides insights on the following pointers”
- Analysis of key drivers (Strong R&D pipeline, Improved relative efficacy of GLP-1 drugs), opportunities (Integration of GLP-1 drugs into telehealth and digital weight management programs), restraints (High barriers for new entrants due to duopoly), and challenges (Off-label use of GLP-1 drugs, High non-adherence to therapy after 12-24 months) influencing the growth of the GLP-1 Analogues market.
- Product Development/ Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the GLP-1 Analogues market.
- Market Development: Comprehensive information about lucrative markets- the report analyses the GLP-1 Analogues market across varied regions.
- Market Diversification: Exhaustive information about new drugs, untapped geographies, recent developments, and investments in the GLP-1 Analogues market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players. A detailed analysis of the key industry players has been done to provide insights into their key strategies, product launches/ approvals, pipeline analysis, acquisitions, partnerships, agreements, collaborations, other recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 analogues market.